NT-3 mimetics: GTS-301 & GTS-302ГТС-301 / ГТС-302
Two experimental peptides, GTS-301 and GTS-302, designed to mimic part of neurotrophin-3, a protein involved in nerve-cell signaling.
What the studies found
Animal research · 2026
Study of the neuroprotective effect of NT-3 dipeptide mimetics GTS-301 and GTS-302 on an experimental model of ischemic stroke
GTS-302 reduced infarct volume by 39% and improved the day-three neurological measure; GTS-301 was inactive in this experiment.
Study notes · methods, sources and limitations
Participants or model Rats with middle cerebral artery occlusion
Important limitations
- Animal experiment, not evidence of benefit in human stroke. Full methods, sample size and risk of bias require review. This is a separate stroke paper; the correction to an earlier NT-3 withdrawal study does not resolve or invalidate this paper automatically.
Pharmacokinetics and Pharmacodynamics. 2026;(1):12–19 · Indexed abstract
Animal research · 2022
The First Dipeptide Mimetic of Neurotrofin-3: Design and Pharmacological Properties.
GTS-301 activated TrkC and TrkB, protected HT-22 cells in injury assays and showed antidepressant-like activity in a mouse forced-swim experiment.
Study notes · methods, sources and limitations
Participants or model Cell cultures and mice
Important limitations
- Preclinical findings do not establish human benefit or safety. Abstract only. Full methods and independent replication remain unconfirmed.
Doklady. Biochemistry and biophysics · Indexed abstract
Animal research · 2024
Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.
GTS-301 and GTS-302 reduced withdrawal signs in morphine-dependent rats; only GTS-302 reduced withdrawal-associated mechanical allodynia. Cell assays reported different downstream signaling, with AKT/mTOR recruitment for GTS-302. The publisher’s 2025 erratum corrects an author’s surname, not experimental results.
Study notes · methods, sources and limitations
Participants or model Morphine-dependent rats and HT-22 cells
Important limitations
- Animal withdrawal models are not evidence for treating opioid dependence in people. The correction changes author spelling only; full experimental methods still require appraisal.
Biochemistry. Biokhimiia · Indexed abstract
About NT-3 mimetics: GTS-301 & GTS-302
Names in this research collection
GTS-301 · GTS-302 · NT-3 · TrkC
Research background
A paired NT-3 research record comparing two loop-4 mimetics with different downstream signaling and animal pharmacology.
- Compound class
- Peptide research family
- Research collection
- Neuropeptide research · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
No human treatment trial assessed for this family
Study methods
Member-specific studies; patents and archival leads identified separately
Independent replication
Independent replication not established by the records collected here
Source access
Primary abstracts, selected full texts, patents and explicit retrieval targets
Safety evidence
Cell and animal effects do not establish human safety; analogues may differ
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Animal research · 2026
Study of the neuroprotective effect of NT-3 dipeptide mimetics GTS-301 and GTS-302 on an experimental model of ischemic stroke
GTS-302 reduced infarct volume by 39% and improved the day-three neurological measure; GTS-301 was inactive in this experiment.
Study notes and original source
Study of the neuroprotective effect of NT-3 dipeptide mimetics GTS-301 and GTS-302 on an experimental model of ischemic stroke
D. M. Nikiforov, P. Yu. Povarnina, T. A. Gudasheva · Pharmacokinetics and Pharmacodynamics. 2026;(1):12–19
GTS-302 reduced infarct volume by 39% and improved the day-three neurological measure; GTS-301 was inactive in this experiment.
- Population / setting
- Rats with middle cerebral artery occlusion
- Source reviewed
- Publisher-deposited abstract and metadata reviewed through Crossref; publisher website could not be retrieved.
Study limitations
- Animal experiment, not evidence of benefit in human stroke.
- Full methods, sample size and risk of bias require review.
- This is a separate stroke paper; the correction to an earlier NT-3 withdrawal study does not resolve or invalidate this paper automatically.
Reviewed 2026-10-05.
Animal research · 2022
The First Dipeptide Mimetic of Neurotrofin-3: Design and Pharmacological Properties.
GTS-301 activated TrkC and TrkB, protected HT-22 cells in injury assays and showed antidepressant-like activity in a mouse forced-swim experiment.
Study notes and original source
The First Dipeptide Mimetic of Neurotrofin-3: Design and Pharmacological Properties.
Gudasheva TA, Sazonova NM, Tarasiuk AV, Logvinov IO, Antipova TA, Nikiforov DM, Povarnina PY, Seredenin SB · Doklady. Biochemistry and biophysics
GTS-301 activated TrkC and TrkB, protected HT-22 cells in injury assays and showed antidepressant-like activity in a mouse forced-swim experiment.
- Population / setting
- Cell cultures and mice
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Animal research · 2024
Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.
GTS-301 and GTS-302 reduced withdrawal signs in morphine-dependent rats; only GTS-302 reduced withdrawal-associated mechanical allodynia. Cell assays reported different downstream signaling, with AKT/mTOR recruitment for GTS-302. The publisher’s 2025 erratum corrects an author’s surname, not experimental results.
Study notes and original source
Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.
Kolik LG, Konstantinopolsky MA, Nikolaev SV, Logvinov IO, Antipova TA, Gudasheva TA · Biochemistry. Biokhimiia
GTS-301 and GTS-302 reduced withdrawal signs in morphine-dependent rats; only GTS-302 reduced withdrawal-associated mechanical allodynia. Cell assays reported different downstream signaling, with AKT/mTOR recruitment for GTS-302. The publisher’s 2025 erratum corrects an author’s surname, not experimental results.
- Population / setting
- Morphine-dependent rats and HT-22 cells
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Animal withdrawal models are not evidence for treating opioid dependence in people.
- The correction changes author spelling only; full experimental methods still require appraisal.
Reviewed 2026-10-05.
Research record · 2025
Erratum to: Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.
The publisher corrects the second author’s surname to Mark A. Konstantinopolsky. The notice does not change experimental results and is not another experiment.
Study notes and original source
Erratum to: Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.
Kolik LG, Konstantinopolsky MA, Nikolaev SV, Logvinov IO, Antipova TA, Gudasheva TA · Biochemistry. Biokhimiia
The publisher corrects the second author’s surname to Mark A. Konstantinopolsky. The notice does not change experimental results and is not another experiment.
- Population / setting
- Correction notice
- Source reviewed
- Complete publisher correction text reviewed: author surname only. Original experimental paper remains abstract-reviewed.
Study limitations
- Author-name correction only; it supplies no new efficacy or safety data.
- Not an independent study or replication.
Reviewed 2026-10-05.
Animal research · 2025
Study of the Pharmacological Activity Spectrum of the New Original NT-3 Mimetic Dipeptide GTS-302.
GTS-302 altered forced-swim, elevated-plus-maze and object-recognition outcomes in rodents, without changing hot-plate pain sensitivity in the reported tests.
Study notes and original source
Study of the Pharmacological Activity Spectrum of the New Original NT-3 Mimetic Dipeptide GTS-302.
Nikiforov DM, Povarnina PY, Gudasheva TA, Nadorova AV, Kolik LG, Valdman EA, Vakhitova YV, Seredenin SB · Doklady. Biochemistry and biophysics
GTS-302 altered forced-swim, elevated-plus-maze and object-recognition outcomes in rodents, without changing hot-plate pain sensitivity in the reported tests.
- Population / setting
- Mice and rats
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Animal research · 2025
Analgesic Activity of the Low Molecular Weight Neurotrophin-3 Dipeptide Mimetic GTS-301.
GTS-301 increased rat tail-flick pain thresholds by about 20–30%, with a reported effect lasting at least 24 hours in this experiment. This endpoint is distinct from the GTS-302 hot-plate test.
Study notes and original source
Analgesic Activity of the Low Molecular Weight Neurotrophin-3 Dipeptide Mimetic GTS-301.
Kolik LG, Konstantinopolsky MA, Sazonova NM, Durnev AD, Gudasheva TA · Doklady. Biochemistry and biophysics
GTS-301 increased rat tail-flick pain thresholds by about 20–30%, with a reported effect lasting at least 24 hours in this experiment. This endpoint is distinct from the GTS-302 hot-plate test.
- Population / setting
- Rats; acute experimental pain testing
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Experiment described in a patent · 2023
Dimeric dipeptide mimetics of neurotrophin-3 — RU2800369C9
The patent describes the NT-3 mimetic series underlying GTS-301 and GTS-302. Patent examples may overlap with later publications and are not independent clinical evidence.
Composite withdrawal index · Reported reductions of 26.9%, 41.4% and 36.5% across three tested exposures · Relative to active control; nonmonotonic dose pattern retained
Study notes and original source
Dimeric dipeptide mimetics of neurotrophin-3 — RU2800369C9
· Primary source linked above
The patent describes the NT-3 mimetic series underlying GTS-301 and GTS-302. Patent examples may overlap with later publications and are not independent clinical evidence.
Results and tables
Reported patent results
Reported findings
GTS-302 reduced the composite withdrawal index while several individual signs and general activity remained unchanged.
Corrected NT-3-mimetic patent containing several preclinical models; selected findings concern GTS-302 in a mouse withdrawal model.
Population or model Corrected NT-3-mimetic patent containing several preclinical models; selected findings concern GTS-302 in a mouse withdrawal model.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Composite withdrawal index | Reported reductions of 26.9%, 41.4% and 36.5% across three tested exposures | Relative to active control; nonmonotonic dose pattern retained |
| Neutral signs | No significant changes in general motor activity, rearing, grooming or several listed withdrawal signs | Not every component improved |
Animal withdrawal scores do not establish treatment of human dependence. Values are specific to GTS-302 and cannot be assigned to all NT-3 mimetics.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Corrected NT-3-mimetic patent containing several preclinical models; selected findings concern GTS-302 in a mouse withdrawal model.
- Source reviewed
- Selected original-source text checked; full methodological review pending.
Study limitations
- Patent claims are not evidence of approved clinical uses.
- Some publications describe shared experiments or have corrections.
Reviewed 2026-11-06.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗